USP1 inhibitors have recently emerged as potential anti-cancer agents and we validated the deubiquitinase activity of USP1–WDR48 as a robust synthetic lethal partner for MSC778 using both genetic and pharmacological approaches (Figs 7F–H and 8, and Supplementary Figs S12 and S13D, E). The gene discussed is USP1; the disease is cancer.